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Steroid androgen hormones play a key role in the progression and treatment of prostate cancer, with androgen
deprivation therapy being the ﬁrst-line treatment used to control cancer growth. Here we apply a novel search
strategy to identify androgen-regulated cellular pathways that may be clinically important in prostate cancer.
Using RNASeq data, we searched for genes that showed reciprocal changes in expression in response to acute an-
drogen stimulation in culture, and androgen deprivation in patients with prostate cancer. Amongst 700 genes
displaying reciprocal expression patterns we observed a signiﬁcant enrichment in the cellular process glycosyl-
ation. Of 31 reciprocally-regulated glycosylation enzymes, a set of 8 (GALNT7, ST6GalNAc1, GCNT1, UAP1, PGM3,
CSGALNACT1, ST6GAL1 and EDEM3) were signiﬁcantly up-regulated in clinical prostate carcinoma. Androgen ex-
posure stimulated synthesis of glycan structures downstream of this core set of regulated enzymes including
sialyl-Tn (sTn), sialyl LewisX (SLeX), O-GlcNAc and chondroitin sulphate, suggesting androgen regulation of the
core set of enzymes controls key steps in glycan synthesis. Expression of each of these enzymes also contributed
toprostate cancer cell viability. This study identiﬁes glycosylation as a global target for androgen control, and sug-
gests loss of speciﬁc glycosylation enzymesmight contribute to tumour regression following androgen depletion
therapy.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Prostate cancer (PCa) is the secondmost common cause ofmale can-
cer death in theUnited States, and there is anurgent need to identify the
keymechanisms that drive clinical disease progression and its response
to treatment, biomarkers for disease progression and therapeutic tar-
gets. Male steroid hormones called androgens play a critical role in
PCa progression, and androgen deprivation therapy (ADT) is the ﬁrst
line treatment for PCa. Although ADT is usually initially effective,
many patients ultimately develop lethal castrate-resistant PCa
(CRPCa) for which treatment options are limited. Androgens control
gene expression via a transcription factor called the androgen receptor
(AR). The AR is essential for PCa cell viability, proliferation and invasion
(Snoek et al., 2009; Hara et al., 2008; Haag et al., 2005), and in CRPCa
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there is a strong selective pressure on cells to maintain AR-regulated
signalling pathways even in lower conditions of circulating androgens.
Progression to CRPCa is thought to involve persistence of AR signalling
and reprogramming of the AR transcriptional landscape (Sharma et al.,
2013;Mills, 2014), duringwhich timeAR activity ismaintained through
activating mutations (Veldscholte et al., 1990; Steinkamp et al., 2009),
gene ampliﬁcation (Visakorpi et al., 1995), AR splice variants (Sun
et al., 2010), or signalling crosstalk with other oncogenic pathways
(Craft et al., 1999).
Classically, androgen binding is thought to promote dimerization of
AR and its translocation to the nucleus where it can act as either a tran-
scriptional enhancer or repressor, depending on the target gene
(Karantanos et al., 2013; Cai et al., 2011). Various genomic and
transcriptomic approaches have been used to identify both AR binding
sites and target genes. However, these studies have generally focused
either on the use of a single model of prostate cancer (LNCaP or its
in vitro derived subclones) (Massie et al., 2007; Wang et al., 2007;
Rajan et al., 2011), only on AR regulated genes with nearby AR genomic
binding sites (Massie et al., 2011; Sharma et al., 2013), or have been lim-
ited by genome coverage on microarrays (Rajan et al., 2011; Massie
et al., 2007, 2011; Wang et al., 2009a). Genome-wide mapping of AR
binding was recently achieved in prostate tissue using chromatin im-
munoprecipitation sequencing (ChIP-seq) (Sharma et al., 2013). This
study successfully revealed an in vivo AR regulated transcriptional
Fig. 1. Reciprocal gene expression signatures identify a core set of clinically relevant androgen-regulated target genes. (A) RNA-Seq expression analysis of LNCaP cells treated with or
without 10 nM R1881 (a synthetic androgen) for 24 h in triplicate, and of 7 PCa patient prostate biopsies before and after androgen ablation therapy (ADT). Venn diagrams show the
number of genes with signiﬁcant differential expression (q b 0.05). Comparison of the two RNA-Seq datasets identiﬁed approximately 700 androgen-regulated genes with reciprocal
regulation. 559 genes were up-regulated by androgen treatment in LNCaP cells, but down-regulated in PCa patient samples following ADT (upper Venn diagram). Conversely, 115
genes were down-regulated by androgen addition in LNCaP cells, but up-regulated in PCa patient samples following ADT (lower Venn diagram). (B) Scatter plot of reciprocally
regulated genes between the two datasets. The X coordinates are expression log2 fold change values of individual genes in LNCaP cells treated with androgens, relative to cells grown
in steroid deplete media. The Y coordinates are log2 fold changes in gene expression of individual genes in the patient dataset after ADT, relative to expression values before
treatment. The log2 fold changes were calculated using the relative FPKM values for each gene. (C) Gene Ontology (GO) analysis of the reciprocally regulated genes identiﬁed 72 terms
with signiﬁcant gene enrichment (p b 0.05). The top 15 signiﬁcantly enriched terms are shown in the graph.
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Fig. 2. Thirty one glycosylation enzymes are regulated by androgens in PCa cells. The term ‘glycosylation’was contained in 7 signiﬁcantly enriched GO terms. (A) Real-time PCR validation
of 31 androgen-regulated glycosylation related genes identiﬁed by GO analyses. LNCaP cells were grown in triplicate either with orwithout 10 nMR1881 (androgens) for 24 h. The Y axis
shows the relative expression changes for each gene with androgens. These 31 glycosylation enzymes were signiﬁcantly down-regulated in 7 PCa patients following ADT (B). The Y axis
shows the relative expression level for each gene (calculated by comparing the FPKM expression values of genes after ADT to the value before treatment). Ourmeta-analysis of clinical PCa
gene expression datasets identiﬁed 8 glycosylation enzymes, which were signiﬁcantly (p b 0.05) upregulated in PCa relative to normal prostate tissue (Supplementary Table 7). (C) Real-
time PCR analysis of glycosylation genes in LNCaP cells treated with or without androgens (10 nM R1881) over a 24 h period.
105J. Munkley et al. / EBioMedicine 8 (2016) 103–116
Fig. 3. Core glycosylation gene signatures in clinical PCa RNA datasets. Meta-analysis of clinical RNA datasets identiﬁed 8 glycosylation enzymeswith signiﬁcant upregulation in PCa tissue
(Supplementary Table 7). (A) Real-time PCR analysis of the expression of UAP1, GCNT1, GALNT7, ST6GAL1, PGM3, EDEM3 and CSGALNACT1 in an independent clinical RNA dataset (BPH v
carcinoma, clinical cohort B). Expression of ST6GALNAC1mRNAwas analysed in these samples previously (Munkley et al., 2015c). The CAMKK2 genewas used as a control. (B) Real-time
PCR analysis of the expression of all 8 glycosylation enzymes inmatched normal and tumour tissue samples from 9 patients (clinical cohort C) tomonitor expression of individual genes in
parallel in individual patients. Upregulated genes are shown in red, downregulated genes in blue, and genes not changing expression in grey (a signiﬁcant gene expression change is
recorded as N1.6 fold change relative to 3 reference genes). Grey indicates there was no signiﬁcant change in gene expression in PCa relative to a matched normal control. Red
indicates signiﬁcant mRNA upregulation, and blue indicates signiﬁcant mRNA downregulation. The bar chart to the right shows that most patients show a pattern where more than
one of the core glycosylation genes increase expression, with typically 4 genes changing expression concurrently. (C) Analysis of glycosylation enzyme mRNA expression in 113
primary prostate cancer tissues (Taylor et al., 2010) indicates signiﬁcant concurrent up-regulation of 18 (out of a possible 28) gene pairs (p values were derived from exact Fisher
tests, p b 0.05). Red indicates signiﬁcant mRNA upregulation, and blue indicates signiﬁcant mRNA downregulation. The bar chart to the right shows that in most patients glycosylation
enzyme enzymes tend to be upregulated concurrently with 4–5 other enzymes.
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Fig. 4.Androgens control expression ofO-glycosylation and core synthesis enzymes, controlling synthesis of the sTn and SLeX antigens. (A) Overview of the catalytic roles GALNT7, ST6GalNAc1
and GCNT1 play in the initiation ofO-glycosylation and core synthesis. (B)Western blot analysis of ST6GalNAc1, GALNT7 and GCNT1 enzymes in LNCaP cells grownwith 10 nMR1881 (andro-
gens, A+) or without (steroid deplete, SD) for 24 or 48 h. Androgen-regulation of each glycosylation enzyme was conﬁrmed using esiRNA mediated depletion of the AR. Actin was used as a
loading control. The speciﬁcity of each antibody used was conﬁrmed by detection of siRNAmediated protein depletion (Supplementary Fig. 1). (C) Detection of cancer-associated O-glycans in
PCa cells, using glycosylation speciﬁc antibodies and ﬂuorescently labelled lectins with binding speciﬁcities to selected sugar moieties. LNCaP cells grown with 10 nM R1881 (androgens) or
without (steroid deplete) for 72 h were labelled with antibodies speciﬁc to the glycans shown. A comparison of the images shows that androgens induce dramatic differences in the glycan
composition of PCa cells. Consistent with previous data (Munkley et al., 2015c), exposure to androgens upregulates the expression of the cancer-associated sialyl-Tn antigen (sTn). Androgen
treatment also upregulates expression of core 1 structures (detected by PNA lectin and Galectin-3 binding) and expression of the Sialyl Lewis X antigen (SLeX). Bar is 10 μM. Similar changes in
glycan signatures in response to androgen stimulation were also observed in androgen-responsive VCaP prostate cancer cells (Supplementary Fig. 4). (D) GALNT7 and GCNT1 expression is
needed for PCa cell viability. For each enzyme siRNA-mediated protein depletion was carried out using two different siRNAs in LNCaP cells grown in full media, and conﬁrmed by western
blot after 72 h. 96 h after transfection the relative number of live cells was calculated. Representative crystal violet stained images are shown below. Further details are given in Supplementary
Fig. 5.
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program in CRPCa (Sharma et al., 2013), but was limited by the chal-
lenges of directly associating an AR binding site with a given gene and
its expression (Barfeld et al., 2014; Wu et al., 2011).
Recent RNA\\Seq analysis ofmetastatic CRPCa revealed that thema-
jority of metastatic PCa harbours clinically actionable molecular alter-
ations (Robinson et al., 2015), providing hope for precision medicine
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in affected individuals. However, despite this ﬁnding, the mechanisms
through which androgens drive the initial development and growth of
PCa remain poorly understood. To address these issues we used RNA-
Seq to comprehensively proﬁle how the PCa transcriptome responds
to androgens. Since previous studies have demonstrated the impor-
tance of cellular context in the functional positioning of the AR
(Sharma et al., 2013), we directly correlated this gene expression data
after androgen stimulation with RNA-Seq data from 7 PCa patients be-
fore and after receiving ADT (Rajan et al., 2014). This combined ap-
proach identiﬁed a core set of nearly 700 genes which were
reciprocally regulated between the two datasets and so are strong can-
didates for being clinically relevant androgen-regulated genes within
localised cancers. Gene-set enrichment of these 700 genes revealed a
multi-factorial link between androgens and the PCa glycoproteome,
and speciﬁcally a core group of 7 glycosylation enzymes that signiﬁcant-
ly change expression in clinical PCa. Importantly, within this core set, 6
enzymes have not previously been implicated in PCa. Our data suggest
that androgen regulation of these 8 core enzymes may be rate limiting
for the expression of cancer-associated glycans and suggests loss of gly-
cosylation enzymes might contribute to tumour regression following
ADT.
2. Materials and Methods
2.1. RNA-Seq and Analysis
For RNA-Seq of LNCaP cells: RNAwas prepared for sequencing using
a RNA Easy Kit (Qiagen 74104). All RNA samples were DNase I treated
using a DNA-free kit (Invitrogen) and stored at −80 °C prior to RNA
quality control check using 2100 Agilent Bioanalyser and mRNA library
prep using TruSeq mRNA library kit (Illumina). Pair-end sequencing
was done in total for six samples (three biological replicates of LNCaP
cells grown in charcoal stripped steroid deplete media, and three bio-
logical replicates from LNCaP cells grown in the presence of 10 nM
R1881 for 24 h) using an Illumina HiSeq 2000. RNA-Seq of RNA from 7
patients before and after ADT (Clinical dataset A) was as described pre-
viously (Rajan et al., 2014). Expression distribution, scatter and volcano
polts for both RNA-Seq datasets are shown in Supplementary Figs. 2a &
2b.
The RNA-Seq analysis of both datasets was carried out as follows:
Differential gene and transcript expression analysis was performed ac-
cording to the Tuxedo protocol (Trapnell et al., 2012). Separately for
each of the clinical (7 patients pre- and post ADT, clinical cohort A),
and cell-line samples (LNCaP cells grown with or without androgens),
all reads were ﬁrst mapped to human transcriptome/genome (build
hg19) with TopHat (Kim et al., 2013) /Bowtie (Langmead and
Salzberg, 2012), followed by per-sample transcript assembly with
Cufﬂinks (Trapnell et al., 2013). Transcript assemblies derived from
the clinical samples were merged together with Cuffmerge (Trapnell
et al., 2013), and differential expression between the two conditions
(prior and post androgen-deprivation therapy) was assessed with
Cuffdiff (Trapnell et al., 2013). Genes/isoforms labelled by the software
as signiﬁcantly differentially expressed were extracted from the results.
The mapped LNCaP data was processed with the same pipeline (with
Cuffmerge, Cuffdiff and Cuffcompare, followed by extraction of
signiﬁcantly differentially expressed genes/isoforms); in this case, ex-
pression changes between cells grown with or without androgens
were assessed. Two subsets of signiﬁcantly differentially expressed
genes were identiﬁed: 1) Genes up-regulated by androgens in LNCaP
cells and down-regulated in 7 patients following androgen-
deprivation therapy. 2) Genes down-regulated by androgens in LNCaP
cells and up-regulated in 7 patients following androgen-deprivation
therapy.
2.2. Gene Ontology Analysis
GO analysis was carried out as described previously (Young et al.,
2010). Enrichment of GO biological processes (with b500 annotations)
was calculated using the goseq R package (version 1.18.0). Genes were
considered signiﬁcant at a p-value threshold of 0.05 after adjustment
using the Benjamini-Hochberg false discovery rate.
2.3. Antibodies
The antibodies and lectins used in the study are listed in Supplemen-
tary Table 1. The speciﬁcity of all of the antibodies usedwas validated by
siRNA mediated protein depletion (Supplementary Fig. 2).
2.4. Cell culture
Cell culture and the cell lines used were as described previously
(Munkley et al., 2014, 2015a,b,c). All siRNA sequences are listed in Sup-
plementary Table 1.
2.5. Clinical Samples
Clinical dataset A: The patient samples used for RNA-Sequencing
were as described previously (Rajan et al., 2014). RNA was obtained
from seven patients with locally advanced metastatic prostate cancer
before and ~22 weeks after ADT. The clinical samples used in clinical
datasets B and C are as described previously (Munkley et al., 2015b,c).
The samples were obtained with ethical approval through the Exeter
NIHR Clinical Research Facility tissue bank (Ref: STB20). Written in-
formed consent for the use of surgically obtained tissue was provided
by all patients.
2.6. RT-qPCR
RT-qPCR was carried out as described previously (Munkley et al.,
2015c). All primer sequences are listed in Supplementary Table 1.
2.7. Cell Viability Analysis
Cell viability analysis was carried out using the TaliR Cell Viability Kit
(Life Technologies A10786) and the TaliR Image-based Cytometer. Rel-
ative cell numbers following siRNA treatment were determined using
the TaliR Image-based Cytometer (Life Technologies).
Fig. 5. Essential enzymes within theO-GlcNAcylation pathway are controlled by androgens in PCa cells. (A) The hexosamine biosynthetic pathway (HBP) catalyses the formation of UDP-
GlcNAc and culminates in the attachment of O-GlcNAc onto serine/threonine residues of target proteins. HBP enzymes regulated by androgens in prostate cancer cells are shown in red.
(B)Western blot analysis of UAP1 and PGM3 enzymes in LNCaP cells grownwith 10 nMR1881 (androgens) or without (steroid deplete) for 24 or 48 h. Androgen-regulation of each gly-
cosylation enzymewas conﬁrmed using esiRNAmediated depletion of the AR. Actin expressionwasmonitored as the loading control. The speciﬁcity of each antibody usedwas conﬁrmed
by detection of siRNAmediated protein depletion (Supplementary Fig. 1). (C) Detection of O-GlcNAcylation in PCa cells, using a glycosylation-speciﬁc antibody and ﬂuorescently labelled
lectins with binding speciﬁcities to O-GlcNAc. LNCaP cells were grownwith 10 nMR1881 (androgens) orwithout (steroid deplete) for 72 h prior to ﬁxation and labelling. A comparison of
the images shows that androgens induce an increase in O-GlcNAc in prostate cancer cells. The size bar represents 10 μM. Similar changes in O-GlcNAc expressionwere also seen in andro-
gen-responsive VCaP prostate cancer cells (Supplementary Fig. 4). (D)UAP1 and PGM3 inﬂuence PCa cell growth and viability in vitro. For each enzyme siRNA-mediated protein depletion
was carried out using two different siRNAs in LNCaP cells grown in full media, and conﬁrmed by western blot after 72 h. The relative number of live cells at 96 h after transfection was
calculated relative to a control non-targeting siRNA. Representative crystal violet stained images are shown below. Further details are given in Supplementary Fig. 5.
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3. Results
3.1. Reciprocal Gene Expression Patterns Identify a Core Set of Clinically
Relevant Androgen-Regulated Target Genes
To analyse how the PCa transcriptome globally responds to andro-
gens we carried out triplicate RNA-Seq of LNCaP cells grown with or
without 10 nMR1881 (a synthetic androgen) in vitro for 24 h. This pro-
cedure identiﬁed 3339 genes which were signiﬁcantly up-regulated by
androgens, and 2760 genes which were signiﬁcantly down-regulated
(q b 0.05) (Supplementary Tables 2 & 3). Since previous studies have
demonstrated a divergence between in vivo and in vitro AR-regulated
genes (Sharma et al., 2013), we correlated our cell line data with RNA-
Seq data from 7 PCa patients before and after ADT(clinical dataset
A) (Rajan et al., 2014). This process identiﬁed nearly 700 potentially
clinically relevant AR target genes that showed reciprocal expression
signatures, indicating that they are both androgen regulated in culture
and have reverse expression switches in patients in response to clinical
ADT (Fig. 1A, B).
3.2. Glycosylation is a Key Cellular Process Regulated by the AR
This comprehensive map of AR-regulated genes in clinical prostate
cancer provides a newwindow through which to understand of the es-
sential signalling pathways downstream of the AR and of the role these
pathways play in both the development of PCa and the response to ADT.
Within our dataset of 700 reciprocally regulated genes were many
established classes of AR target genes, including cell cycle regulators
(e.g. ORC5L), signalling molecules implicated in PCa (e.g. HER3), and
genes with roles in central metabolism and biosynthetic pathways
(e.g. CAMKK2), as well as many additional novel androgen-regulated
genes (Supplementary Tables 4 & 5). Gene Ontology (GO) analysis of
these 700 genes identiﬁed known AR regulated processes including
lipid and cholesterol biosynthesis (Wu et al., 2014; Suburu and
Chen, 2012; Swinnen et al., 1997b), fatty acid metabolism
(Swinnen et al., 1997a; Swinnen et al., 2000; Liu, 2006), and re-
sponse to ER stress (Segawa et al., 2002; Sheng et al., 2015) (Supple-
mentary Table 6). Also, in addition to these previously known
androgen-regulated cellular processes, ‘glycosylation’ was speciﬁ-
cally identiﬁed as a previously unidentiﬁed androgen-regulated pro-
cess, with a signiﬁcant enrichment of genes encoding glycosylation
enzymes within the dataset (Fig. 1C).
As mounting evidence links changes in the glycan composition of
PCa cells to disease progression (Chen et al., 2014; Itkonen and Mills,
2013; Itkonen et al., 2014; Munkley et al., 2015c, 2016), we further
analysed our RNA\\Seq data to identify 31 individual genes encoding
glycosylation enzymes that display reciprocal gene expression between
androgen stimulation in vitro, and ADT in patients (Fig. 2A, B). Meta-
analysis of publically available clinical gene expression data across 326
samples in 3 large datasets (Taylor et al., 2010; Varambally et al.,
2005; Grasso et al., 2012), and into two independent clinical RNA
datasets, further resolved a subset of glycosylation genes that are addi-
tionally signiﬁcantly up-regulated in PCa relative to the normal prostate
gland (p b 0.05) (Supplementary Table 7). These genes are shown in red
in Fig. 2A, B. Of these genes, UAP1 and ST6GalNAc1 are known AR target
genes that have previously been linked with PCa progression (Itkonen
et al., 2014;Munkley et al., 2015c;Munkley and Elliott, 2016b). Howev-
er, to the best of our knowledge, this study is the ﬁrst time that
androgen-regulation of the other 6 genes (GCNT1, GALNT7, PGM3,
CSGALNACT1, ST6GAL1, and EDEM3) has been described. Each of these
6 newly identiﬁed AR-regulated glycosylation enzyme genes showed
a rapid pattern of activation following androgen stimulation in culture,
suggesting they are early targets of the AR (Fig. 2C). Consistent with
them being physiological targets of the AR, transcription of these
genes was also activated by a range of R1881 concentrations, and
inhibited by the AR antagonist Casodex® (Supplementary Fig. 3). We
also conﬁrmed androgen-regulation of all 8 glycosylation enzymes in
the androgen-responsiveVCaP prostate cancer cell line (Supplementary
Fig. 4).
Our meta-analysis made use of two independent clinical RNA val-
idation cohorts, which were analysed using real-time PCR. The ﬁrst
cohort compared RNA samples of benign prostatic hyperplasia
(BPH) versus prostate carcinoma obtained from 49 patients (clinical
dataset B) (Fig. 3A), and the second cohort compared carcinoma ver-
sus adjacent normal tissue within 9 patients (clinical dataset
C) (Fig. 3B). 7 out of the 8 glycosylation enzyme genes examined
were signiﬁcantly up-regulated in at least one of these two cohorts,
with 5 genes (ST6GalNAc1, GALNT7, UAP1, CSGALNACT1 and EDEM3)
signiﬁcantly up-regulated in both cohorts (p b 0.05) (Supplementary
Table 7).
Further analysis of our cohort of patient tissue RNA from carcinoma
versus normal tissue (clinical dataset C) also showed that several of the
8 glycosylation genes often changed expression in parallel, with the ma-
jority of patients showing a concurrent change in 4 or 5 out of the 8 indi-
vidual genes (Fig. 3B). Analysis of a larger dataset (Taylor et al., 2010) for
concurrent expression of the 8 glycosylation enzymes found 18 signiﬁ-
cant associations (Fig. 3C), suggesting that changes in glycosylation
gene expression in PCa generally co-occur for several genes in parallel
within tumours.
3.3. Androgens Control Expression of O-Glycosylation and Core Synthesis
Enzymes that are Essential for Viability of PCa Cells
The above data indicates that androgens control the gene expression
of at the transcriptional level of enzymes operating at multiple steps
within the glycosylation synthetic pathways. We next tested whether
this set of 8 individual glycosylation enzymes are upregulated by andro-
gens at the protein level, and whether these enzymes are functionally
important in prostate cancer cells. Three glycosylation enzyme genes,
GALNT7, ST6GalNAC1 and GCNT1 map to the O-glycosylation pathway
(Fig. 4A). Initiation of O-glycosylation is carried out by a family of
GALNT sialyltransferase enzymes, including GALNT7, which catalyse
the transfer of GalNAc to serine and threonine residues on target pro-
teins to produce the Tn antigen (Ten Hagen et al., 2003). The Tn antigen
can be modiﬁed by ST6GalNAc1 to produce the truncated cancer-
associated sTn antigen (Sewell et al., 2006), or can be converted to
core 1 O-glycan structures. Core 1 or the T antigen is then converted
to core 2 by one of three core 2 enzymes (GCNT1, 2 and 3).We previous-
ly showed that ST6GalNAc1 and the sialyl-Tn (sTn) cancer-associated
antigen it produces are directly regulated by androgens in PCa cells
(Munkley et al., 2015c; Munkley and Elliott, 2016b). Here, in addition
to androgen regulation of ST6GalNAc1,we additionally show androgen
control of the O-glycosylation enzymes GALNT7 and GCNT1 (4B,
upper panel). Furthermore and consistent with these enzymes being
under control of the androgen receptor, protein induction in response
to androgen treatment was blocked by siRNA mediated depletion of
Fig. 6.Androgens control synthesis of chondroitin sulphate in PCa cells. (A) Initiation of chondroitin sulphate (CS) synthesis ismediated by two enzymes, CSGalNAcT1 and CSGalNAcT2, of
which CSGalNAcT1 is androgen regulated (shown in red). (B) Real-time PCR analysis of CSGalNAcT1mRNA over a range of concentrations of R1881 (androgens) in LNCaP cells. (C) Real-
time PCR analysis of CSGalNAcT1mRNA in LNCaP cells treatedwith the AR antagonist CasodexR in the presence of 10 nMR1881. (D) Detection of both CS and the CS proteoglycan versican
in PCa cells grownwith orwithout androgens (10 nMR1881) for 72 h. Androgen-regulation of the enzyme is for CSGalNAcT1 conﬁrmed at themRNA level only (wewere unable to obtain
an antibody against the human CSGalNAcT1 protein which worked in our hands). The size bar is equivalent to 10 μM. Similar changes were also seen in VCaP prostate cancer cells
(Supplementary Fig. 4). (E) siRNA-mediated protein depletion of CSGalNAcT1 in LNCaP cells grown in full media using two different siRNAs was conﬁrmed by real-time PCR after 72 h
(upper left panel). The relative number of live, dead and apoptotic cells 96 h after transfection was calculated for each siRNA relative to a control non-targeting siRNA using ﬂow
cytometry. Representative crystal violet stained images are shown below.
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the AR (Fig. 4B, lower panel). GCNT1 is important for formation of core 2
branched O-glycans and has been implicated in synthesis of the cancer-
associated Sialyl Lewis X (SLeX) antigen (Chen et al., 2014). As well as
upregulation of GCNT1, we also observed increased expression of SLeX
in PCa cells in response to androgen stimulation (Fig. 4C, Supplementary
Fig. 4), indicating that androgen control of GCNT1 is likely to be an
important regulatory step in this glycan synthetic pathway. We also
found that in both LNCaP and VCaP cells that androgen exposure leads
to up-regulated expression of the core 1 Thomsen-Friedenreich antigen
(T-antigen, detected by PNA lectin), which is produced by the GALNT7
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enzyme. Also consistent with an up-regulation of core 1 glycans in PCa
cells exposed to androgens, we observed an increased binding of the
soluble lectin Galectin-3, which binds core 1 glycans (Newlaczyl and
Yu, 2011)(Fig. 4C, Supplementary Fig. 4).
To test whether changes in the expression of GALNT7 and GCNT1
contribute to PCa viability, we individually depleted cells of these en-
zymes using siRNAs. Loss of both enzymes resulted in a signiﬁcant re-
duction in cell number and signiﬁcantly reduced cell viability 96 h
after siRNA treatment, in comparison to cells treated with the control
siRNA (p b 0.02, Fig. 4D and Supplementary Figs. 5 & 6). Taken together,
our data suggests that the O-glycosylation and core synthesis enzymes
GALNT7, ST6GalNAC1 and GCNT1 are induced by androgens in PCa
cells at the protein level, and that production of these enzymes could
be important for the synthesis of important cancer-associated O-
glycans and contribute to PCa cell viability.
3.4. Essential EnzymesWithin the O-GlcNAcylation Pathway are Controlled
by Androgens in PCa Cells
The identity of the core set of 8 androgen regulated glycosylation en-
zymes identiﬁed above also suggest that the hexosamine biosynthesis
pathway (HBP) is under more extensive androgen control in PCa cells
than previously realised. The HBP produces an amino-sugar conjugate
UDP-N-acetylglucoamine (UDP-GlcNAc), which provides a substrate
for posttranslational modiﬁcation of proteins (Wellen et al., 2010)
(Fig. 5A). While it was previously known that the HBP enzyme UAP1
is directly regulated by androgens in PCa cells (Itkonen et al., 2014),
our reciprocal analysis demonstrated that the PGM3 enzyme is also
androgen-regulated via the AR (Figs. 2 and 5B).
Further supporting the hypothesis that the glycans produced by the
HBP are also under androgen control, we detected increased O-GlcNAc
in PCa cells exposed to androgens (detected by a glycosylation speciﬁc
antibody and two glycan speciﬁc lectins, Fig. 5C and Supplementary
Fig. 4). Depletion of either UAP1 or PGM3with two independent siRNAs
signiﬁcantly reduced cell viability of both LNCaP and CWR22Rv1 cells in
comparison to cells treated with the control siRNA, consistent with ex-
pression of both these enzymes being important for prostate cancer cell
survival (Fig. 5D, Supplementary Figs. 5 & 6).
3.5. Androgens Control Synthesis of Chondroitin Sulphate in PCa Cells
The identity of the core set of 8 androgen regulated genes we iden-
tiﬁed by our reciprocal analysis further predicted that synthesis of chon-
droitin sulphate (CS) is under androgen control in PCa cells, via
activation of CSGalNacT1 expression. While six glycosyltransferases are
involved in CS synthesis, the enzyme chondroitin sulphate N-
acetylgalactosaminyltransferase 1 (CSGalNAcT1) is involved in the initi-
ation and elongation processes (Sakai et al., 2007; Watanabe et al.,
2010) (Fig. 6A). We conﬁrmed androgen regulation of CSGalNacT1 ex-
pression in LNCaP and VCaP cells (Fig. 6B, C and Supplementary
Fig. 4). In PCa cells treated with androgens we found increased CS syn-
thesis, indicating that CSGalNacT1 is likely to be a key control point for
synthesis of this CS glycan (Fig. 6D left panels). CS forms the GAG side
chains of several proteoglycan families, including the PCa associated
large CS proteoglycan, Versican. Consistent with previous reports, we
also found that the Versican is regulated by androgens in PCa cells
(Read et al., 2007) (Fig. 6D right panel). Depletion of CSGalNAcT1
using two different siRNAs very dramatically reduced CSGALNACT1
mRNA expression as monitored by qPCR. Decreased expression of
CSGALNACT1 also increased the numbers of dead and apoptotic cells,
and signiﬁcantly decreased cell viability in both LNCaP and CWR22Rv1
cells in comparison to cells treated with the control siRNA, suggesting
a key role for the CSGALNACT1 enzyme in PCa cell biology (Fig. 6E and
Supplementary Figs. 5 & 6).
3.6. N-GlycanModiﬁcations are Controlled by Androgens in Prostate Cancer
Cells
Our data further predicted that that N-glycan synthesis is also under
androgen control in PCa cells, via expression control of the ST6GAL1 and
EDEM3 genes. ST6GAL1 encodes a sialyltransferase that catalyses the
transfer of sialic acid onto terminal galactose containing N-glycan sub-
strates (Schultz et al., 2013; Hedlund et al., 2008) (Fig. 7A). We con-
ﬁrmed expression of ST6GAL1 protein is regulated by androgens in
PCa cells by western blot (Fig. 7B). While we observed an increase in
ST6GAL1 expression in both LNCaP and VCaP cells in response to andro-
gen stimulation, there was no corresponding increase in sialylation of
terminal N-glycans detected by SNA binding (Fig. 7Ci and Supplementa-
ry Fig. 4) suggesting the inﬂuence of this enzyme on terminal sialylation
may be dependent upon cellular background. Supporting such a model,
expression of ST6GAL1 in DU145 PCa cells did increase SNA binding
(Fig. 7Cii). Although it did not detectably increase sialylation of terminal
N-glycans, depletion of ST6GAL1 using two different siRNAs led to re-
duced cell viability in both LNCaP andCWR22Rv1 cells (Fig. 7D and Sup-
plementary Figs. 5 & 6) indicating ST6GAL1 has an important biological
role in these cell lines.
EDEM3 stimulatesmannose trimming of N-glycans from total glyco-
proteins, and also enhances glycoprotein endoplasmic reticulum-
associated degradation (ERAD) of misfolded glycoproteins (Hirao
et al., 2006; Olivari and Molinari, 2007) (Fig. 7A), which is particularly
important in the context of cancer where increased metabolic needs
lead to the accumulation of faulty proteins (Olzmann et al., 2013). We
conﬁrmed androgen regulation of EDEM3 protein expression in PCa
cells (Fig. 7B). Consistent with this we also found that an increase in
branched N-glycans (detected by ConA lectin) in response to androgen
treatment (Fig. 7Ciii). siRNA depletion experiments with two indepen-
dent siRNAs showed that expression of EDEM3 enzyme is important for
PCa cell viability and growth (Fig. 7E and Supplementary Figs. 5 & 6).
4. Discussion
Although aberrant glycosylation is common in cancer and has been
linked to PCa progression (Munkley et al., 2016), our understanding of
what drives these cancer associated glycan changes has been scant
and has relied upon anecdotal observations. Here, using a global
transcriptomic analysis to identify genes that have a reciprocal expres-
sion signature between androgen deprivation therapy in patients and
androgen stimulation in culture, we identify glycosylation as a cohesive
enriched pathway that is under extensive control by androgen hor-
mones. A total of 31 genes encoding glycosylation enzymes were re-
vealed through reciprocal expression signatures, and of these we
further identify a core set of 8 androgen regulated glycosylation
Fig. 7.N-Glycanmodiﬁcations are controlled by androgens in prostate cancer cells. (A) ST6GAL1 is a sialytransferasewhich catalyses the addition of terminal sialic acid residues ontoN-glycans.
EDEM3 mediates the trimming of N-glycans, which are then further modiﬁed by other enzymes. (B) Western blot analysis of ST6GAL1 and EDEM3 in LNCaP cells grown with 10 nM R1881
(androgens) or without (steroid deplete) for 24 or 48 h. Androgen-regulation of ST6GAL1 and EDEM3was conﬁrmed using esiRNAmediated depletion of the AR, which blocks up-regulation
of both proteins. GAPDHwas used as a loading control. (C) (i) Detection of sialic acid in LNCaP cells grownwith orwithout androgens for 72 h, and in (ii) DU145 cells over-expressing either EV
control or ST6GAL1using SNA lectin. Althoughoverall sialic acid expression did not increasewith exposure to androgens in LNCaP cells, over-expression of ST6GAL1 inDU145 cells does result in
an increase. (iii) Detection of branched N-glycans in LNCaP cells using ﬂuorescently labelled ConA lectin. Cells treated with androgens (10 nM R1881) for 72 h have increased ConA binding
relative to cells grown without androgens (steroid deplete). (D,E) siRNA-mediated protein depletion of ST6GAL1 and EDEM3 in LNCaP cells grown in full media using two different siRNAs
was conﬁrmed by western blot after 72 h. The relative number of live, dead and apoptotic cells 96 h after transfection was relative to a control non-targeting siRNA using ﬂow cytometry
(upper right panels). Representative crystal violet stained images are shown below.
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enzymes that are also signiﬁcantly up-regulated in multiple cohorts of
clinical PCa material. Signiﬁcantly, only two of these 8 genes,
ST6GalNAc1 and UAP1, have previously been identiﬁed to have roles in
clinical PCa (Munkley et al., 2015c; Itkonen et al., 2014). The remaining
6 genes are identiﬁed as androgen regulated by our dataset, and reveal
new control points throughwhich these glycan synthesis pathways can
be regulated in cells, and new mechanisms through which androgens
regulate the behaviour of PCa cells.We ﬁndeachof these 8 glycosylation
enzymes are important for PCa cell viability, suggesting that loss of
these enzymes in response to ADTmightmake an important and previ-
ously unknown contribution to tumour regression in patients.
Glycosylated proteins and other glycoconjugates are major cellular
components which have been causally associated with all of the hall-
marks of cancer (Munkley andElliott, 2016a). Altered activity or expres-
sion of glycosylation enzymes in cancer cells can lead to glycan
modiﬁcations to alter cell-cell adhesion, migration, interactions with
the cell matrix, immune surveillance, signalling and cellularmetabolism
andmaymodify these processes in PCa (Munkley et al., 2016). Glycosyl-
ation pathways produce glycan structures via the cumulative enzymatic
activity of many glycosylation enzymes. The core set of 8 androgen reg-
ulated glycosylation genes that we identify here belong to the O-glycan,
HBP, chondroitin sulphate, andN-glycan synthetic pathways that are al-
ready known to be important in cancer.
O-glycans are altered in the early stages of cellular transformation,
and are important for cancer initiation, invasion and metastasis (Pinho
and Reis, 2015). We showed previously that induction of the O-
glycosylation enzyme ST6GalNAc1 by androgens in prostate cancer
cells can reduce prostate cancer cell adhesion (Munkley et al., 2015c;
Munkley and Elliott, 2016b). In this study we conﬁrm androgen regula-
tion of ST6GalNAc1 and show for the ﬁrst time a link between andro-
gens and two additional O-glycosylation enzymes in prostate cancer,
GALNT7 and GCNT1. Expression of GALNT7 has previously been found
to be up-regulated in several cancer types, including PCa (Chen et al.,
2014; Li et al., 2014; Peng et al., 2012; Gaziel-Sovran et al., 2011), and
is linked to metastasis and invasion in nasopharyngeal carcinoma (Nie
et al., 2015). As GALNT7 initiates O-glycosylation to produce the Tn an-
tigen, upregulation of this enzyme could potentially be linked to a range
of changes in O-glycans in prostate cancer cells. The Tn antigen can be
further modiﬁed by ST6GalNAc1 to produce sTn raising the possibility
for a role for GALNT7 in the expression of this important cancer associ-
ated antigen. GALNT7 may also have a role in the synthesis of the T-
antigen, which is frequently over-expressed in cancer (Hanisch and
Baldus, 1997; Cazet et al., 2010; Spinger, 1984) and is associated with
the adhesion of PCa cells to the endothelium (Glinsky et al., 2001). In
cancer, truncated O-glycans often recruit carbohydrate binding pro-
teins, or lectins that can play a key role in disease progression and me-
tastasis (Munkley, 2016). Here we show increased binding of
Galectin-3 in prostate cancer cells treatedwith androgens. These results
are important, as Galectin-3 has been implicated in PCa tumour growth,
and suggested as a potential therapeutic target (Wang et al., 2009b).
Our data are also the ﬁrst to suggest a link between the AR and expres-
sion of GCNT1 in prostate cancer. Increased GCNT1 expression has al-
ready been linked to PCa progression, shown to increase prostate
tumour growth in vivo, and been implicated in synthesis of the
cancer-associated SLeX antigen (Chen et al., 2014; Hagisawa et al.,
2005; Kojima et al., 2015). Here, we show for the ﬁrst time that expres-
sion of both GCNT1 and the SLeX antigen are regulated by androgens in
prostate cancer cells. SLeX is a major sialylated antigen associated with
poor prognosis and metastasis in PCa, and has been detected on PSA
and MUC1 proteins from patients with PCa (Chen et al., 2014).
Multiple levels of evidence presented here also suggest that in addi-
tion to theO-glycan pathway, three othermajor glycosylation pathways
important in PCa are under the control of androgens. Firstly, one of these
pathways is the HBP, which creates the amino-sugar conjugate O-
GlcNAc which is known to be elevated in PCa (Kamigaito et al., 2014).
O-GlcNAc is so important it has been suggested as a new hallmark of
cancer (Fardini et al., 2013). Our data shows that expression levels of
the two ﬁnal two enzymes in the HBP are controlled by androgens, as
is the expression of the O-GlcNAc glycan itself. Secondly, we also detect
androgen regulation of the pathway producing chondroitin sulphate
(CS) and of CS itself, which is a type of GAG (glycosaminoglycan) pres-
ent in extracellular matrices and on the surface of many cell types
(Gandhi and Mancera, 2008). CS is increased in metastatic PCa
(Ricciardelli et al., 2009a; Ricciardelli et al., 1997), where it is thought
to play a role in cellular proliferation and differentiation (Hardingham
and Fosang, 1992). Expression of the large CS proteoglycan Versican,
which is linked to cell adhesion and associated with poor outcomes in
many different cancers including PCa (Ricciardelli et al., 2009b), also re-
sponds to androgens.
Thirdly, we also ﬁnd that androgens control production of two key
enzymes involved in N-glycan processing; ST6GAL1 and EDEM3.
ST6GAl1 is important for controlling sialylation of N-terminal glycans,
and is over-expressed in many types of cancer (Swindall et al., 2013).
Altered sialylation has long been associated with cancer cell metastasis,
invasion and survival (Pinho and Reis, 2015; Munkley, 2016). Expres-
sion of ST6GAL1 is already linked to the epithelial-mesenchymal transi-
tion (EMT) and malignancy (Lu et al., 2014), but the mechanisms
driving these changes remain poorly understood. EDEM3 controls man-
nose trimming of N-glycans, and has previously been shown to be up-
regulated in malignant PCa as part of a glycosylation gene signature
(Chen et al., 2014). β1,6GlcNAc tri/tetra branched N-glycans and cryptic
N-glycans are detected in PCa and have been linked to metastasis and
are being investigated as potential biomarkers (Ishibashi et al., 2014;
Wang et al., 2013). It is possible that the elevated levels of EDEM3
plays a role in creating these aberrant N-glycans.
PCa is a unique and confounding disease, characterised by prognos-
tic heterogeneity and there is a key clinical need to develop biomarkers
to help distinguish indolent from aggressive disease, aswell as to devel-
op new treatments for advanced PCa. Our study identifying glycosyla-
tion as an androgen-regulated process in PCa has important clinical
implications both diagnostically and therapeutically. The most widely
used serological biomarkers for cancer diagnosis and monitoring are
glycoproteins, andmonitoring the glycan composition of speciﬁc glyco-
proteins can dramatically increase their speciﬁcity as biomarkers (Reis
et al., 2010). Numerous studies have examined whether a tumour spe-
ciﬁc glycan signature on prostate speciﬁc antigen (PSA) can be used to
distinguish between BPH and PCa (Gilgunn et al., 2013) and there are
ongoing studies analysing the glycan composition of serum, plasma,
exosomes, expressed-prostatic secretions (EPS) ﬂuids and formalin-
ﬁxed, parafﬁn-embedded (FFPE) tissues to diagnose PCa and determine
prognosis (Yoneyama et al., 2014; Kyselova et al., 2007; Drake and
Kislinger, 2014; Powers et al., 2013, 2014; Drake et al., 2015). Our
study identiﬁes a panel of glycosylation enzymes and their correspond-
ing antigens as potentially important in prostate cancer. An increased
understanding of how glycosylation inﬂuences prostate cancer cell be-
haviour should aid in the development of glycosylation speciﬁc bio-
markers for use in the early detection and management of PCa.
Glycans also likely play roles in all aspects of cancer progression and
are therefore attractive targets for therapeutic intervention (Munkley
and Elliott, 2016a). Previous work has shown that inhibiting glycosyla-
tion, even in conditions where the AR is active, can reduce PCa cell via-
bility (Itkonen and Mills, 2013). An increased understanding of how
glycosylation modulates the biological function of prostate cancer cells
will allow the development of a relatively unexploited ﬁeld of drugs
based on inhibitors, glycan antagonists and glycan functionmodulators.
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